Zivo Bioscience, Inc. announced additional findings from its 42-day coccidiosis challenge study that demonstrate the product?s positive impact on the cost of broiler production as an alternative to commonly-used antibiotics. ZIVO?s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. These new results, along with earlier findings, further demonstrate the benefits of ZIVO?s product across the broiler production value chain.

ZIVO previously reported the effects of its product on the health of broiler chickens exposed to coccidiosis during the course of a 42-day grow out period, which is typical for the poultry industry. These health benefits included a statistically significant reduction in intestinal damage caused by the Eimeria parasite compared with untreated control birds. This improvement in intestinal health following parasite exposure was on par with the market-leading commercial ionophore.

ZIVO now reports that this reduction in intestinal damage enables poultry farms to optimize feed utilization as measured by the Feed Conversion Ratio (FCR), which is the primary driver of profitability. Similar to the outcomes related to intestinal damage, ZIVO?s product resulted in a statistically significant improvement in FCR compared with untreated controls. Further, these results were not statistically different from the market-leading commercial ionophore.